UK: In the age of AMR, does a nationalised drug company make sense? The case for and against
A UK economist has come out saying that pharma companies are dragging their heels in the fight against superbugs and the only resolution would be creating a state-run drug company. Could he be right, or is international support and funding for a competitive marketplace the best solution to developing new lifesaving antibiotics? The editorial team put forward the arguments for and against a national drug company.
Emerging Antimicrobials and Diagnostics in AMR 2019
International Matchmaking Symposium on 19-20 November, 2019 in Amsterdam, The Netherlands.